Antidiabetic medications mainly contribute to the remission of metabolic syndrome, such as improved obesity, hypertension, and dyslipidemia, which are known to be associated with increased cancer risk
kind gift from Lauge Schffer, Novo Nordisk, Denmark [23]), GLP-1 receptor antagonist Ex9 (1 mol/l
The average starting BMI of the 50 enrolled subject was 43.2 kg/m2 (or 271 pounds) and 64% had type 2 diabetes or prediabetes
58 GLP-1RAs potentially may reduce the risk of AF onset and progression through direct and indirect effects on atrial remodelling, including a reduction in systemic inflammation, improvement of cardiomyocyte metabolism, autonomic nervous system modulation, regulation of intracellular Ca 2+ levels and prevention and possibly reversion of atrial fibrosis
Cost was not considered in the recommendations